SEARCH

SEARCH BY CITATION

References

  • 1
    Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995; 345: 93944.
  • 2
    Adlard JW, Richman SD, Seymour MT, Quirke P. Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol 2002; 3: 7582.
  • 3
    Iacopetta B, Grieu F, Joseph D, Elsaleh H. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001; 85: 82730.
  • 4
    Leichman L, Lenz HJ, Leichman CG, Groshen S, Danenberg K, Baranda J, Spears CP, Boswell W, Silberman H, Ortega A, et al. Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur J Cancer 1995; 31A: 130610.
  • 5
    Metzger R, Danenberg K, Leichman CG, Salonga D, Schwartz EL, Wadler S, Lenz HJ, Groshen S, Leichman L, Danenberg PV. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998; 4: 23716.
  • 6
    Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6: 13227.
  • 7
    Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J, Romero A, Machiavelli M, De Lena M, Allegra CJ, Johnston PG. Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 2000; 82: 5607.
  • 8
    Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, Lionetto R, Maley F, Sobrero A. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 1999; 17: 176070.
  • 9
    Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA,Jr, Stemmerman G, Wells JD, Macdonald JS, Meyskens FL,Jr. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 1998; 58: 114958.
  • 10
    Liang JT, Huang KC, Cheng YM, Hsu HC, Cheng AL, Hsu CH, Yeh KH, Wang SM, Chang KJ. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. Int J Cancer 2002; 97: 4517.
  • 11
    Elsaleh H, Powell B, McCaul K, Grieu F, Grant R, Joseph D, Iacopetta B. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 2001; 7: 13439.
  • 12
    McKay JA, Lloret C, Murray GI, Johnston PG, Bicknell R, Ahmed FY, Cassidy J, McLeod HL. Application of the enrichment approach to identify putative markers of response to 5-fluorouracil therapy in advanced colorectal carcinomas. Int J Oncol 2000; 17: 1538.
  • 13
    Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 2003; 9: 2898903.
  • 14
    Barratt PL, Seymour MT, Stenning SP, Georgiades I, Walker C, Birbeck K, Quirke P. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 2002; 360: 138191.
  • 15
    Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 24757.
  • 16
    Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, Cabrera BL, Goel A, Arnold CA, Miyai K, Boland CR. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004; 126: 394401.
  • 17
    Zou Z, Anisowicz A, Hendrix MJ, Thor A, Neveu M, Sheng S, Rafidi K, Seftor E, Sager R. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994; 263: 5269.
  • 18
    Maass N, Hojo T, Rosel F, Ikeda T, Jonat W, Nagasaki K. Down regulation of the tumor suppressor gene maspin in breast carcinoma is associated with a higher risk of distant metastasis. Clin Biochem 2001; 34: 3037.
  • 19
    Hojo T, Akiyama Y, Nagasaki K, Maruyama K, Kikuchi K, Ikeda T, Kitajima M, Yamaguchi K. Association of maspin expression with the malignancy grade and tumor vascularization in breast cancer tissues. Cancer Lett 2001; 171: 10310.
  • 20
    Maass N, Nagasaki K, Ziebart M, Mundhenke C, Jonat W. Expression and regulation of tumor suppressor gene maspin in breast cancer. Clin Breast Cancer 2002; 3: 2817.
  • 21
    Zou Z, Zhang W, Young D, Gleave MG, Rennie P, Connell T, Connelly R, Moul J, Srivastava S, Sesterhenn I. Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation. Clin Cancer Res 2002; 8: 11727.
  • 22
    Xia W, Lau YK, Hu MC, Li L, Johnston DA, Sheng S, El-Naggar A, Hung MC. High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma. Oncogene 2000; 19: 2398403.
  • 23
    Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, Khalkhali-Ellis Z, Arbour N, Seftor EA, Hendrix MJ. The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res 2002; 8: 292432.
  • 24
    Maass N, Hojo T, Ueding M, Luttges J, Kloppel G, Jonat W, Nagasaki K. Expression of the tumor suppressor gene Maspin in human pancreatic cancers. Clin Cancer Res 2001; 7: 8127.
  • 25
    Ogasawara S, Maesawa C, Yamamoto M, Akiyama Y, Wada K, Fujisawa K, Higuchi T, Tomisawa Y, Sato N, Endo S, Saito K, Masuda T. Disruption of cell-type-specific methylation at the Maspin gene promoter is frequently involved in undifferentiated thyroid cancers. Oncogene 2004; 23: 111724.
  • 26
    Akiyama Y, Maesawa C, Ogasawara S, Terashima M, Masuda T. Cell-type-specific repression of the maspin gene is disrupted frequently by demethylation at the promoter region in gastric intestinal metaplasia and cancer cells. Am J Pathol 2003; 163: 19119.
  • 27
    Heighway J, Knapp T, Boyce L, Brennand S, Field JK, Betticher DC, Ratschiller D, Gugger M, Donovan M, Lasek A, Rickert P. Expression profiling of primary non-small cell lung cancer for target identification. Oncogene 2002; 21: 774963.
  • 28
    Smith SL, Watson SG, Ratschiller D, Gugger M, Betticher DC, Heighway J. Maspin—the most commonly-expressed gene of the 18q21.3 serpin cluster in lung cancer—is strongly expressed in preneoplastic bronchial lesions. Oncogene 2003; 22: 867787.
  • 29
    Sugimoto S, Maass N, Takimoto Y, Sato K, Minei S, Zhang M, Hoshikawa Y, Junemann KP, Jonat W, Nagasaki K. Expression and regulation of tumor suppressor gene maspin in human bladder cancer. Cancer Lett 2004; 203: 20915.
  • 30
    Reis-Filho JS, Torio B, Albergaria A, Schmitt FC. Maspin expression in normal skin and usual cutaneous carcinomas. Virchows Arch 2002; 441: 5518.
  • 31
    Umekita Y, Ohi Y, Sagara Y, Yoshida H. Expression of maspin predicts poor prognosis in breast-cancer patients. Int J Cancer 2002; 100: 4525.
  • 32
    Ito Y, Yoshida H, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Matsuura N, Kuma K, Miyauchi A. Maspin expression is directly associated with biological aggressiveness of thyroid carcinoma. Thyroid 2004; 14: 138.
  • 33
    Hirai K, Koizumi K, Haraguchi S, Hirata T, Mikami I, Fukushima M, Yamagishi S, Kawashima T, Okada D, Shimizu K, Kawamoto M. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer. Ann Thorac Surg 2005; 79: 24853.
  • 34
    Boltze C. Loss of maspin is a helpful prognosticator in colorectal cancer: a tissue microarray analysis. Pathol Res Pract 2005; 200: 78390.
  • 35
    Bettstetter M, Woenckhaus M, Wild PJ, Rummele P, Blaszyk H, Hartmann A, Hofstadter F, Dietmaier W. Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer. J Pathol 2005; 205: 60614.
  • 36
    Wittekind SA. TNM Classification of malignant tumours, 6th ed. New York: Wiley-Liss, 2002.
  • 37
    Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Ruschoff J. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res 1997; 57: 474956.
  • 38
    Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 524857.
  • 39
    Brett MC, Pickard M, Green B, Howel-Evans A, Smith D, Kinsella A, Poston G. p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. Eur J Surg Oncol 1996; 22: 1825.
  • 40
    van Rijnsoever M, Elsaleh H, Iacopetta B. Microsatellite instability in colorectal cancer: prognostic, predictive or both? Am J Pathol 2002; 160: 3845; author reply 385–6.
  • 41
    Allegra CJ, Kim G, Kirsch IR. Microsatellite instability in colon cancer. N Engl J Med 2003; 349: 17746; author reply 1774–6.
  • 42
    Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23: 60918.
  • 43
    Cher ML, Biliran HR,Jr, Bhagat S, Meng Y, Che M, Lockett J, Abrams J, Fridman R, Zachareas M, Sheng S. Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proc Natl Acad Sci USA 2003; 100: 784752.
  • 44
    Sheng S, Carey J, Seftor EA, Dias L, Hendrix MJ, Sager R. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci USA 1996; 93: 1166974.
  • 45
    Song SY, Lee SK, Kim DH, Son HJ, Kim HJ, Lim YJ, Lee WY, Chun HK, Rhee JC. Expression of maspin in colon cancers: its relationship with p53 expression and microvessel density. Dig Dis Sci 2002; 47: 18315.
  • 46
    Sheng S, Pemberton PA, Sager R. Production, purification, and characterization of recombinant maspin proteins. J Biol Chem 1994; 269: 3098893.
  • 47
    Ruschoff J, Dietmaier W, Luttges J, Seitz G, Bocker T, Zirngibl H, Schlegel J, Schackert HK, Jauch KW, Hofstaedter F. Poorly differentiated colonic adenocarcinoma, medullary type: clinical, phenotypic, and molecular characteristics. Am J Pathol 1997; 150: 181525.
  • 48
    Jass JR, Do KA, Simms LA, Iino H, Wynter C, Pillay SP, Searle J, Radford-Smith G, Young J, Leggett B. Morphology of sporadic colorectal cancer with DNA replication errors. Gut 1998; 42: 6739.
  • 49
    Samowitz WS, Holden JA, Curtin K, Edwards SL, Walker AR, Lin HA, Robertson MA, Nichols MF, Gruenthal KM, Lynch BJ, Leppert MF, Slattery ML. Inverse relationship between microsatellite instability and K-ras and p53 gene alterations in colon cancer. Am J Pathol 2001; 158: 151724.